Browse ACSBG1

Summary
SymbolACSBG1
Nameacyl-CoA synthetase bubblegum family member 1
Aliases BGM; FLJ30320; MGC14352; BG1; KIAA0631; hsBG; bubblegum; lipidosin; GR-LACS; hsBGM; Long-chain-fatty-acid--C ......
Chromosomal Location15q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Cytoplasmic vesicle Microsome Endoplasmic reticulum
Domain PF00501 AMP-binding enzyme
Function

Mediates activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. Able to activate long-chain fatty acids. Also able to activate very long-chain fatty acids; however, the relevance of such activity is unclear in vivo. Can activate diverse saturated, monosaturated and polyunsaturated fatty acids.

> Gene Ontology
 
Biological Process GO:0000038 very long-chain fatty acid metabolic process
GO:0001676 long-chain fatty acid metabolic process
GO:0006631 fatty acid metabolic process
GO:0006637 acyl-CoA metabolic process
GO:0006732 coenzyme metabolic process
GO:0006790 sulfur compound metabolic process
GO:0007272 ensheathment of neurons
GO:0008366 axon ensheathment
GO:0009108 coenzyme biosynthetic process
GO:0031960 response to corticosteroid
GO:0035336 long-chain fatty-acyl-CoA metabolic process
GO:0035337 fatty-acyl-CoA metabolic process
GO:0035338 long-chain fatty-acyl-CoA biosynthetic process
GO:0035383 thioester metabolic process
GO:0035384 thioester biosynthetic process
GO:0042552 myelination
GO:0044272 sulfur compound biosynthetic process
GO:0046949 fatty-acyl-CoA biosynthetic process
GO:0048545 response to steroid hormone
GO:0051186 cofactor metabolic process
GO:0051188 cofactor biosynthetic process
GO:0051384 response to glucocorticoid
GO:0071616 acyl-CoA biosynthetic process
Molecular Function GO:0004467 long-chain fatty acid-CoA ligase activity
GO:0015645 fatty acid ligase activity
GO:0016874 ligase activity
GO:0016877 ligase activity, forming carbon-sulfur bonds
GO:0016878 acid-thiol ligase activity
GO:0031957 very long-chain fatty acid-CoA ligase activity
GO:0102391 decanoate--CoA ligase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa03320 PPAR signaling pathway
hsa04920 Adipocytokine signaling pathway
hsa00061 Fatty acid biosynthesis
hsa00071 Fatty acid degradation
hsa01100 Metabolic pathways
hsa01212 Fatty acid metabolism
Reactome R-HSA-75105: Fatty Acyl-CoA Biosynthesis
R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-75876: Synthesis of very long-chain fatty acyl-CoAs
R-HSA-75109: Triglyceride Biosynthesis
Summary
SymbolACSBG1
Nameacyl-CoA synthetase bubblegum family member 1
Aliases BGM; FLJ30320; MGC14352; BG1; KIAA0631; hsBG; bubblegum; lipidosin; GR-LACS; hsBGM; Long-chain-fatty-acid--C ......
Chromosomal Location15q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ACSBG1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolACSBG1
Nameacyl-CoA synthetase bubblegum family member 1
Aliases BGM; FLJ30320; MGC14352; BG1; KIAA0631; hsBG; bubblegum; lipidosin; GR-LACS; hsBGM; Long-chain-fatty-acid--C ......
Chromosomal Location15q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ACSBG1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolACSBG1
Nameacyl-CoA synthetase bubblegum family member 1
Aliases BGM; FLJ30320; MGC14352; BG1; KIAA0631; hsBG; bubblegum; lipidosin; GR-LACS; hsBGM; Long-chain-fatty-acid--C ......
Chromosomal Location15q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ACSBG1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0470.92
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1390.852
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0010.999
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1760.778
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3790.782
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.890.531
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.7490.232
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3030.74
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.0230.278
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2770.604
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0940.901
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2580.491
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ACSBG1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.81.413.40.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.81.713.10.032
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolACSBG1
Nameacyl-CoA synthetase bubblegum family member 1
Aliases BGM; FLJ30320; MGC14352; BG1; KIAA0631; hsBG; bubblegum; lipidosin; GR-LACS; hsBGM; Long-chain-fatty-acid--C ......
Chromosomal Location15q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ACSBG1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolACSBG1
Nameacyl-CoA synthetase bubblegum family member 1
Aliases BGM; FLJ30320; MGC14352; BG1; KIAA0631; hsBG; bubblegum; lipidosin; GR-LACS; hsBGM; Long-chain-fatty-acid--C ......
Chromosomal Location15q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ACSBG1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ACSBG1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolACSBG1
Nameacyl-CoA synthetase bubblegum family member 1
Aliases BGM; FLJ30320; MGC14352; BG1; KIAA0631; hsBG; bubblegum; lipidosin; GR-LACS; hsBGM; Long-chain-fatty-acid--C ......
Chromosomal Location15q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ACSBG1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolACSBG1
Nameacyl-CoA synthetase bubblegum family member 1
Aliases BGM; FLJ30320; MGC14352; BG1; KIAA0631; hsBG; bubblegum; lipidosin; GR-LACS; hsBGM; Long-chain-fatty-acid--C ......
Chromosomal Location15q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ACSBG1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolACSBG1
Nameacyl-CoA synthetase bubblegum family member 1
Aliases BGM; FLJ30320; MGC14352; BG1; KIAA0631; hsBG; bubblegum; lipidosin; GR-LACS; hsBGM; Long-chain-fatty-acid--C ......
Chromosomal Location15q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ACSBG1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolACSBG1
Nameacyl-CoA synthetase bubblegum family member 1
Aliases BGM; FLJ30320; MGC14352; BG1; KIAA0631; hsBG; bubblegum; lipidosin; GR-LACS; hsBGM; Long-chain-fatty-acid--C ......
Chromosomal Location15q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ACSBG1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ACSBG1.
ID Name Drug Type Targets #Targets
DB083262-(6-HYDROXY-1,3-BENZOTHIAZOL-2-YL)-1,3-THIAZOL-4(5H)-ONESmall MoleculeACSBG11